Evidence map›Paper›PMID 32362671›Full record

ArticleThe Canadian journal of hospital pharmacy

Stability of Methadone Hydrochloride for Injection in Saline Solution.

M Mihaela Friciu, Hugo Alarie, Mylène Beauchemin, Jean-Marc Forest, Grégoire Leclair

Abstract read
In one paragraph

Article in The Canadian journal of hospital pharmacy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. The Canadian journal of hospital pharmacy
    Article
  4. Medication Safety-A Global Health Priority.The Canadian journal of hospital pharmacy
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M Mihaela Friciu, MSc, is a Research Associate with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, BSc, is a Master of Science candidate in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, PharmD, MSc, is a Pharmacist with the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, DPH, MSc, is a Pharmacist with the Compounding Service (Fabrication) in the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, PhD, is an Associate Professor with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Hugo Alarie, MSc, is a Research Associate with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, BSc, is a Master of Science candidate in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, PharmD, MSc, is a Pharmacist with the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, DPH, MSc, is a Pharmacist with the Compounding Service (Fabrication) in the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, PhD, is an Associate Professor with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Mylène Beauchemin, MSc, is a Research Associate with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, BSc, is a Master of Science candidate in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, PharmD, MSc, is a Pharmacist with the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, DPH, MSc, is a Pharmacist with the Compounding Service (Fabrication) in the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, PhD, is an Associate Professor with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Jean-Marc Forest, MSc, is a Research Associate with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, BSc, is a Master of Science candidate in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, PharmD, MSc, is a Pharmacist with the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, DPH, MSc, is a Pharmacist with the Compounding Service (Fabrication) in the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, PhD, is an Associate Professor with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Grégoire Leclair, MSc, is a Research Associate with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, BSc, is a Master of Science candidate in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, PharmD, MSc, is a Pharmacist with the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, DPH, MSc, is a Pharmacist with the Compounding Service (Fabrication) in the Department of Pharmacy, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, BPharm, PhD, is an Associate Professor with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUntil October 2014, methadone hydrochloride for injection (10 mg/mL) was available in Canada through Health Canada's Special Access Programme. Diluted to 5 mg/mL in saline, it was used in pediatrics for acute and cancer-related pain. More recently, the department of pharmacy of the Centre hospitalier universitaire Sainte-Justine in Montréal, Quebec, proposed compounding a solution of methadone hydrochloride for injection (5 mg/mL) from bulk powder and saline solution for pediatric administration.

objectiveTo assess the stability of the proposed compounded preparation.

methodsSolutions of methadone hydrochloride in saline were prepared from bulk powder and stored in clear glass vials for up to 180 days at room temperature (25 °C) or with refrigeration (5 °C), with testing on days 0, 7, 14, 30, 60, 90, and 180. The appearance of the solutions and presence of particulate matter were assessed. A stability-indicating high-performance liquid chromatography (HPLC) method was developed to assay the concentration of methadone over time.

resultsNo notable changes in appearance of the methadone solution were observed, particle counts did not exceed limits specified by the

conclusionsMethadone hydrochloride for injection prepared from bulk powder in saline solution at a concentration of 5 mg/mL remained chemically stable for at least 180 days when stored in clear glass vials at 5 °C and at 25 °C.

Indexed as

injectionmethadonepowderstability

Identifiers

PMID32362671
PMCPMC7182366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.